Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01300026 | AMG 319 Lymphoid Malignancy FIH | completed | Phase 1 | 28 | AmgenINDUSTRY | 1 | Feb 9, 2017 | clinicaltrials |
| NCT02071927 | Study of the Glutaminase Inhibitor CB-839 in Leukemia | completed | Phase 1 | 43 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00201682 |
| completed |
| Phase 1 / Phase 2 |
| 36 |
| John ByrdOTHER |
| 1 |
| Feb 8, 2017 |
| clinicaltrials |
| NCT00586690 | Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT | completed | Phase 1 | 47 | David Rizzieri, MDOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT01471782 | Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 93 | Amgen Research (Munich) GmbHINDUSTRY | 7 | Feb 8, 2017 | clinicaltrials |
| NCT00082225 | LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)(ACDAL) | terminated | Phase 1 | 4 | Baylor College of MedicineOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00233506 | A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated | completed | Phase 1 | 41 | University of IowaOTHER | 1 | Feb 6, 2017 | clinicaltrials |
| NCT00989586 | Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 35 | Beth ChristianOTHER | 1 | Feb 6, 2017 | clinicaltrials |
| NCT02598570 | Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma | completed | Phase 1 | 7 | AbbVieINDUSTRY | 1 | Feb 6, 2017 | clinicaltrials |
| NCT01300247 | A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON) | completed | Phase 1 | 41 | Genentech, Inc.INDUSTRY | 1 | Feb 2, 2017 | clinicaltrials |
| NCT00633594 | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 39 | SCRI Development Innovations, LLCOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT01029054 | Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT01991938 | Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma | terminated | Phase 1 | 75 | Verastem, Inc.INDUSTRY | 2 | Jan 27, 2017 | clinicaltrials |
| NCT01810120 | Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT | completed | Phase 1 / Phase 2 | 30 | Mariella EnocOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT00323323 | CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas | completed | Phase 1 | 24 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT02953808 | Phase 1 Study of GSK2315698 in Healthy Japanese Subjects | completed | Phase 1 | 18 | GlaxoSmithKlineINDUSTRY | 1 | Jan 19, 2017 | clinicaltrials |
| NCT00536341 | Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 64 | SCRI Development Innovations, LLCOTHER | 1 | Jan 16, 2017 | clinicaltrials |
| NCT01032148 | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT02697552 | Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma | completed | Phase 1 | 13 | HUYABIO International, LLC.INDUSTRY | 1 | Jan 12, 2017 | clinicaltrials |
| NCT00477035 | Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies | completed | Phase 1 | 22 | Sally AraiOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT00741403 | A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies | completed | Phase 1 | 39 | Cornerstone PharmaceuticalsINDUSTRY | 2 | Dec 29, 2016 | clinicaltrials |
| NCT03005392 | Home-exercise Program for Children and Adolescent Survivors of Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 24 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Dec 29, 2016 | clinicaltrials |
| NCT00334438 | Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 23, 2016 | clinicaltrials |
| NCT01944982 | Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma(HNJ-NKAES-2012) | terminated | Phase 1 / Phase 2 | 7 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 20, 2016 | clinicaltrials |
| NCT00104975 | Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 1 | 20 | Yale UniversityOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT02861040 | Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT02987244 | Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT01555853 | Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma | terminated | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02892695 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02983942 | Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 50 | Beijing Tiantan HospitalOTHER | 1 | Dec 6, 2016 | clinicaltrials |
| NCT00091624 | A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) | completed | Phase 1 | 77 | Celgene CorporationINDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT00226993 | Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides. | withdrawn | Phase 1 / Phase 2 | 0 | Stanford UniversityOTHER | 0 | Dec 1, 2016 | clinicaltrials |
| NCT01908413 | Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 23 | Curis, Inc.INDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT02757248 | Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL | withdrawn | Phase 1 | 0 | Anne Beaven, MDOTHER | 0 | Dec 1, 2016 | clinicaltrials |
| NCT00874562 | Rapamycin in Relapsed Acute Lymphoblastic Leukemia | completed | Phase 1 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT01745354 | Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) | terminated | Phase 1 | 6 | Robert LowskyOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02968472 | A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia | unknown | Phase 1 | 30 | The First People's Hospital of YunnanOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02965157 | Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma | unknown | Phase 1 / Phase 2 | 15 | Beijing Biohealthcare Biotechnology Co.,LtdINDUSTRY | 1 | Nov 16, 2016 | clinicaltrials |
| NCT00825149 | A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma(GAUDI) | completed | Phase 1 | 137 | Hoffmann-La RocheINDUSTRY | 6 | Nov 4, 2016 | clinicaltrials |
| NCT00854126 | A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 38 | Genentech, Inc.INDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT00854152 | A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 121 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT00930514 | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma | completed | Phase 1 | 281 | Hoffmann-La RocheINDUSTRY | 22 | Nov 2, 2016 | clinicaltrials |
| NCT01122875 | A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma | completed | Phase 1 | 14 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01356173 | Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma | completed | Phase 1 | 10 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01432353 | A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 39 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00634179 | A Phase I/II Trial of VR-CHOP in Lymphoma Patients | completed | Phase 1 / Phase 2 | 37 | Emory UniversityOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT02819583 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Oct 25, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Feb 9, 2017source: clinicaltrials